Company News & Media

– Appointment of Current Director Michael Cavanaugh as Interim Chief Executive Officer – – Promotion of Current Controller and Counsel Richard McKilligan to Chief Financial Officer – LOS ANGELES, CA (MARKETWIRED – May 14, 2019) – Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals,...

LOS ANGELES, CA – (April 25, 2019) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that Dr. Avtar Dhillon has decided to resign...

LOS ANGELES, Jan. 24, 2019 — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce that it has added an additional position on...

LOS ANGELES, CA – (GLOBE NEWSWIRE – December 3, 2018) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the...

Company appoints two new directors including the Hon. Edward Feighan as new Chairman of the Board LOS ANGELES, CA – (MARKETWIRED – November 20, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Financing to support company at least into 2020 and for the initiation of multiple Phase 2 clinical trials LOS ANGELES, CA – (October 23, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Focused on remyelination, a form of neural repair that may benefit multiple sclerosis as well as addiction, stroke, and schizophrenia LOS ANGELES, CA – (October 3, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for...

Dr. Brandon Zipp to discuss outlook for Vitality’s VBX-100 THC prodrug in scientific presentation held at UCLA LOS ANGELES, CA – (September 13, 2018) – Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment...

During safety pharmacology screening Vitality’s THC prodrug demonstrates no signs of adverse or off-target effects LOS ANGELES, CA – August 21, 2018 – Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious...

Approval of Vitality research program and manufacturing operations through May 2019 LOS ANGELES, June 20, 2018 — Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it...